(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter

  1. Wei Ni,
  2. Claudia S. Wilhelm,
  3. Michael Bader,
  4. Dennis L. Murphy,
  5. Keith Lookingland and
  6. Stephanie W. Watts
  1. Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan (W.N., K.L., S.W.W.); Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany (C.S.W., M.B.); and Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland (D.L.M.)
  1. Address correspondence to:
    Dr. Wei Ni, Department of Pharmacology and Toxicology, B445 Life Sciences Bldg., Michigan State University, East Lansing, MI 48824-1317. E-mail: niwei{at}msu.edu

Abstract

(+)-Norfenfluramine, the major metabolite of fenfluramine, causes vasoconstriction dependence on the 5-hydroxytryptamine (5-HT)2A receptor in rat. (+)-Norfenfluramine was reported as a 5-hydroxytryptamine transporter (5-HTT) substrate and 5-HT releaser. Because the arterial 5-HTT exists and is functional in the rat, we hypothesized that (+)-norfenfluramine causes vasoconstriction by releasing 5-HT from vascular smooth muscle via 5-HTT. The released 5-HT, in turn, activates the 5-HT2A receptor. Isometric contractility experiments showed that (+)-norfenfluramine-induced mouse aortic contraction was reduced by the 5-HTT inhibitor fluoxetine (1 μM) but not by fluvoxamine (1 μM). Tryptophan hydroxylase (TPH)-deficient (Tph1/–) mice lack peripheral 5-HT. (+)-Norfenfluramine (10 nM–100 μM)-contracted aorta from wild-type and Tph1–/– mice with equivalent potency (–log EC50 [M], wild type = 5.73 ± 0.02, Tph1–/– = 5.62 ± 0.09), and these contractions were inhibited by the 5-HT2A receptor antagonist ketanserin (3 nM) by a similar magnitude in aorta from wild-type and Tph1–/– mice (wild type = 19.4, Tph1–/– = 15.4-fold rightward shift versus control), as did fluoxetine (1 μM) (wild type = 22.4, Tph1–/– = 28.8-fold rightward shift versus control). To further test the role of 5-HTT in (+)-norfenfluramine-induced aortic contraction, the 5-HTT-targeted mutation mouse was used. (+)-Norfenfluramine induced similar aortic contraction in wild-type and 5-HTT-targeted mutation mice, and these contractions were inhibited by fluoxetine (1 μM). Thus, (+)-norfenfluramine vasoconstriction is not dependent on 5-HTT-mediated release of endogenous 5-HT but by activating membrane 5-HT2A receptors directly. Understanding of the mechanism by which (+)-norfenfluramine induces vasoconstriction is important to characterize and understand the function of the serotonergic system in peripheral arterial vasculature.

Footnotes

  • This study was supported by National Institutes of Health Grant HL58489 and American Heart Association Grant 0415397Z.

  • doi:10.1124/jpet.105.087080.

  • ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; 5-HTT, 5-hydroxytryptamine transporter; TPH, tryptophan hydroxylase; HPLC, high-pressure liquid chromatography; 5-HIAA, 5-hydroxyindole acetic acid; PBS, phosphate-buffered saline; TBS, Tris-buffered saline; OCT, organic cation transporter; PSS, physiological salt solution; 5-HTT KO, 5-HTT-targeted mutation mouse; NET, norepinephrine transporter.

    • Received March 31, 2005.
    • Accepted May 12, 2005.
« Previous | Next Article »Table of Contents